Vitality Watch

Dossier pubmed review 14-jul-2026
Narrative review or expert overview without new data

A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.

Key claim: Circulating SASP factors, notably GDF15 and Activin A, can noninvasively index senescence burden and associate with neurodegeneration, pulmonary, cardiometabolic, and musculoskeletal decline, and are modulated by emerging drug and lifestyle senotherapeutics.

Abstract

Cellular senescence is a hallmark of aging and a contributing factor to many age-related morbidity and decline. A key characteristic of senescent cells is a pro-inflammatory secretome known as the senescence-associated secretory phenotype (SASP). When tracked in circulation, SASP factors associate with age-related clinical traits and diseases, raising the captivating possibility that the senescence burden, and concomitant susceptibility to age-related morbidity, can be noninvasively assessed in clinical settings. This review consolidates human-focused evidence identifying these biomarkers of senescence in circulation, and emerging drug and lifestyle-based senotherapeutic interventions that modulate senescence burden and associated clinical parameters. Clinical parameters associated with the circulating senescence burden generally fall into four interrelated health domains: neurodegeneration, pulmonary disease, cardiometabolic disease, and musculoskeletal disorders. For each domain, the biological basis for the negative impact of senescence is explored in clinical and preclinical models, revealing that the accumulation of senescence often suppresses stemness throughout the body, suggesting that senescence plays a causal role in age-related decline and highlighting potential novel therapeutic avenues. Importantly, some circulating biomarkers of senescence, such as GDF15 and Activin A, demonstrate cross-study clinical relevance and are implicated in morbidities across multiple health domains. Collectively, these insights provide a framework for understanding the role that senescence plays in aging and the development of diagnostic biomarker panels that could better inform future clinical care.

Why this matters

Human translation of senescence biology has lacked a validated noninvasive readout: this compendium nominates GDF15 and Activin A as the two cross-study-replicated plasma SASP factors that index systemic senescence burden across four clinical domains and respond to candidate senotherapeutics. If these hold up in prospective trials, they offer a pragmatic plasma biomarker layer to evaluate senolytic/senomorphic effects in humans rather than relying on tissue biopsies — but both markers are also elevated by many non-senescence stressors (cachexia, mitochondrial disease, pregnancy), so specificity for senescent-cell burden remains the open question gating their use as outcome measures.

Source

Link

Briefing card

A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.
Stage: review · pubmed · 14-jul-2026

If you are following or enrolled in senolytic or senomorphic trials, blood markers like GDF15 and Activin A are the circulating readouts most likely to be used to track whether the intervention is engaging senescent cells.

Circulating SASP factors, notably GDF15 and Activin A, can noninvasively index senescence burden and associate with neurodegeneration, pulmonary, cardiometabolic, and musculoskeletal decline, and are modulated by emerging drug and lifestyle senotherapeutics.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.arr.2026.103254

build build 880 · 2bcef25 · 2026-11-18